These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31952447)

  • 1. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
    Lefere S; Devisscher L; Tacke F
    Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
    [No Abstract]   [Full Text] [Related]  

  • 2. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
    Tacke F
    Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
    Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
    Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty liver disease: time to target CCR5?
    Brata VD; Tacke F
    Expert Opin Ther Targets; 2024 May; 28(5):335-339. PubMed ID: 38857170
    [No Abstract]   [Full Text] [Related]  

  • 7. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
    Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
    PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cenicriviroc in the management of nonalcoholic fatty liver disease.
    Neokosmidis G; Tziomalos K
    World J Gastroenterol; 2018 Dec; 24(48):5415-5417. PubMed ID: 30622370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice.
    Chen G; Yu Y; Zhu Y; Nagashimada M; Wang Y; Nagata N; Xu L
    Endocrinology; 2024 May; 165(7):. PubMed ID: 38862137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells.
    Madan U; Verma B; Awasthi A
    Eur J Immunol; 2024 Jul; 54(7):e2350847. PubMed ID: 38643381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How effective are nonalcoholic fatty liver disease models for drug discovery?
    Hundertmark J; Tacke F
    Expert Opin Drug Discov; 2020 Nov; 15(11):1237-1240. PubMed ID: 32524859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
    Ratziu V; Sanyal A; Harrison SA; Wong VW; Francque S; Goodman Z; Aithal GP; Kowdley KV; Seyedkazemi S; Fischer L; Loomba R; Abdelmalek MF; Tacke F
    Hepatology; 2020 Sep; 72(3):892-905. PubMed ID: 31943293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
    Visseaux B; Charpentier C; Collin G; Bertine M; Peytavin G; Damond F; Matheron S; Lefebvre E; Brun-Vézinet F; Descamps D;
    PLoS One; 2015; 10(8):e0134904. PubMed ID: 26247470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.
    Alkhouri N
    Expert Opin Investig Drugs; 2020 Feb; 29(2):87. PubMed ID: 31984804
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
    Friedman SL; Ratziu V; Harrison SA; Abdelmalek MF; Aithal GP; Caballeria J; Francque S; Farrell G; Kowdley KV; Craxi A; Simon K; Fischer L; Melchor-Khan L; Vest J; Wiens BL; Vig P; Seyedkazemi S; Goodman Z; Wong VW; Loomba R; Tacke F; Sanyal A; Lefebvre E
    Hepatology; 2018 May; 67(5):1754-1767. PubMed ID: 28833331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists.
    Junker A; Kokornaczyk AK; Zweemer AJ; Frehland B; Schepmann D; Yamaguchi J; Itami K; Faust A; Hermann S; Wagner S; Schäfers M; Koch M; Weiss C; Heitman LH; Kopka K; Wünsch B
    Org Biomol Chem; 2015 Feb; 13(8):2407-22. PubMed ID: 25566983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis.
    Song X; Jiang C; Yu M; Lu C; He X
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1597-1605. PubMed ID: 38744472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model.
    Bober A; Piotrowska A; Pawlik K; Ciapała K; Maciuszek M; Makuch W; Mika J
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success.
    Drenth JPH; Schattenberg JM
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.